World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
41323
World Ranking
11125
National Ranking
5724

Frank L. Meyskens publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Frank L. Meyskens sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 538 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Frank L. Meyskens D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Frank L. Meyskens sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 92 D-Index — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Frank L. Meyskens is affiliated with the University of California, Irvine in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a focus on Pharmaceutical Science, Oncology, Molecular Biology, Epidemiology, and Dermatology.

Their recent publications cover topics related to skin cancer chemoprevention, advanced drug delivery systems, and aging, including:

  • Topical Delivery of Carvedilol Loaded Nano-Transfersomes for Skin Cancer Chemoprevention, 2020, Pharmaceutics
  • Prediction of disability-free survival in healthy older people, 2022, GeroScience
  • Recent Advances in Clinical Research for Skin Cancer Chemoprevention, 2023, Cancers
  • Transfersome Encapsulated with the R-carvedilol Enantiomer for Skin Cancer Chemoprevention, 2023, Nanomaterials
  • Topical carvedilol delivery prevents UV-induced skin cancer with negligible systemic absorption, 2021, International Journal of Pharmaceutics

Frequent co-authors in Meyskens's publications include Bradley T. Andresen, Ayaz Shahid, Jeffrey Wang, Kristen M. Kelly, and Ying Huang. These collaborations have contributed to consistent research output in the fields noted above.

Publication venues where Meyskens's work appears frequently include:

  • Cancers
  • Pharmaceutics
  • GeroScience
  • Nanomaterials
  • International Journal of Pharmaceutics

Main research topics explored by Meyskens encompass:

  • Advancements in Transdermal Drug Delivery
  • Skin Protection and Aging
  • Cutaneous Melanoma Detection and Management
  • Lipid Membrane Structure and Behavior
  • Nonmelanoma Skin Cancer Studies
  • Advanced Drug Delivery Systems
  • Frailty in Older Adults

Best Publications

  • EFFECTS OF A COMBINATION OF BETA CAROTENE AND VITAMIN A ON LUNG CANCER AND CARDIOVASCULAR DISEASE

    Gilbert S. Omenn;Gary E. Goodman;Gary E. Goodman;Mark D. Thornquist;John Balmes

  • Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

    Scott M. Lippman;Eric A. Klein;Eric A. Klein;Phyllis J. Goodman;M. Scott Lucia

  • Vitamin E and the Risk of Prostate Cancer: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)

    Eric A. Klein;Ian M. Thompson;Catherine M. Tangen;John J. Crowley

  • Risk Factors for Lung Cancer and for Intervention Effects in CARET, the Beta-Carotene and Retinol Efficacy Trial

    Gilbert S. Omenn;Gary E. Goodman;Mark D. Thornquist;John Balmes

  • Polyamines and cancer: old molecules, new understanding

    Eugene W. Gerner;Frank L. Meyskens

  • Reactive Oxygen Species: A Breath of Life or Death?

    John P. Fruehauf;Frank L. Meyskens

  • Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

    Jack Cuzick;Florian Otto;Florian Otto;John A Baron;Powel H Brown

  • Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma

    Lowell A. Goldsmith;Frederic B. Askin;Alfred E. Chang;Cynthia Cohen

  • Development of difluoromethylornithine (DFMO) as a chemoprevention agent.

    Frank L. Meyskens;Eugene W. Gerner

  • Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

    Halle C F Moore;Joseph M. Unger;Kelly Anne Phillips;Frances Boyle;Frances Boyle

  • Prevention and early detection of prostate cancer

    Jack Cuzick;Mangesh A Thorat;Gerald L Andriole;Otis W Brawley;Otis W Brawley

  • Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial

    Frank L. Meyskens;Christine E. McLaren;Daniel Pelot;Sharon Fujikawa-Brooks

  • Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia.

    Robert E. Carroll;Richard V. Benya;Danielle Kim Turgeon;Shaiju Vareed

  • The Beta-Carotene and Retinol Efficacy Trial: Incidence of Lung Cancer and Cardiovascular Disease Mortality During 6-Year Follow-up After Stopping β-Carotene and Retinol Supplements

    Gary E. Goodman;Mark D. Thornquist;John Balmes;Mark R. Cullen

  • Rationale and Strategies for Chemoprevention of Cancer in Humans

    John S. Bertram;Laurence N. Kolonel;Frank L. Meyskens

  • Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia

    Joyce A. O’Shaughnessy;Gary J. Kelloff;Gary B. Gordon;Andrew J. Dannenberg

  • Retinoids as preventive and therapeutic anticancer agents (Part I).

    Lippman Sm;Kessler Jf;Meyskens Fl

  • Quality of Life End Points in Cancer Clinical Trials: Review and Recommendations

    Carol McMillen Moinpour;Polly Feigl;Barbara Metch;Katherine A. Hayden

  • Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.

    Dennis J. Ahnen;Polly Feigl;Gang Quan;Cecelia Fenoglio-Preiser

  • Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy

    Halle C.F. Moore;Joseph M. Unger;Kelly Anne Phillips;Frances Boyle;Frances Boyle

Frequent Co-Authors

David S. Alberts
David S. Alberts University of Arizona
Eugene W. Gerner
Eugene W. Gerner University of Arizona
Hoda Anton-Culver
Hoda Anton-Culver University of California, Irvine
Scott M. Lippman
Scott M. Lippman University of California, San Diego
Sydney E. Salmon
Sydney E. Salmon University of Arizona
Eric A. Klein
Eric A. Klein Cleveland Clinic
Dawn L. Hershman
Dawn L. Hershman Columbia University
Ian M. Thompson
Ian M. Thompson The University of Texas Health Science Center at San Antonio
Timothy R. Morgan
Timothy R. Morgan California State University, Long Beach
Gilbert S. Omenn
Gilbert S. Omenn University of Michigan–Ann Arbor

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA doesn’t have to mean following a single, traditional route. For those looking for flexibility or different entry points into the healthcare field, a variety of online degrees and career pathways are available.

If you already hold an RN license and are seeking to advance your career, you can explore what is the cheapest rn to bsn program online to help you earn your BSN affordably. For individuals who do not have a nursing background but want to become a nurse practitioner, direct entry nurse practitioner programs for non-nurses online offer a fast-tracked option.

Non-nurses interested in an entry-level role can consider online adn programs for non nurses, which can be less competitive to access and completed online. For those interested in healthcare but not in clinical roles, online medical coding classes with financial aid present another viable pathway into the medical field.

These flexible online options make it easier to start or advance a healthcare career without the barriers of traditional classroom learning.

Best Scientists Citing Frank L. Meyskens

Trending Scientists

Recently Published Articles